Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Inspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for ...

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Despite short-term volatility and reliance on GLP-1 momentum, HIMS remains a long-term bullish play in the consumer digital ...

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong ...

Gland Pharma Ltd announced a significant 49.9% increase in its net profit for Q1FY26, reaching ₹215.4 crore due to robust operating margins.

Aetna’s multi-year margin recovery is a top priority, and CVS is making progress through organizational realignment, ...